Navigation Links
Delcath to Present at the Lazard Healthcare Conference on November 15
Date:11/11/2011

NEW YORK, Nov. 11, 2011 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that Eamonn P. Hobbs, President and CEO, will present at the Lazard Capital Markets' Eighth Annual Healthcare Conference on Tuesday, November 15, 2011 at 4:00 P.M. ET in New York, NY.  Mr. Hobbs will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only.  Delcath will offer a live webcast and subsequent archived replay of its presentation, which may be accessed at http://www.delcath.com/investors/events/.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, CE Marking for the Generation Two system, the timing of our commercial launch in Europe, adoption, use and resulting sales, if any, for  CHEMOSAT in the EEA, our ability to successfully commercialize CHEMOSAT and the potential of the chemosaturation therapy as a treatment for patients with cancers in the liver, acceptability of the clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future Delcath system for chemosaturation in the United States and foreign markets for the same or  other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for CHEMOSAT, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

Media Contact:Doug Sherk/Gregory Gin

Janine McCargoEVC Group

EVC Group415-568-4887/646-445-4801

646-688-0425
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Announces Fiscal 2011 Third Quarter Results and Recent Developments
2. Delcath Systems to Report Third Quarter Progress and Conduct Conference Call
3. FDA Schedules Delcath Pre-New Drug Application Meeting Date
4. Delcath Announces Completion of Regulatory Notification Process in New Zealand
5. Delcath Announces Updated Efficacy Results From Phase 3 Trial of Chemosaturation for Melanoma Metastases in the Liver Presented at European Multidisciplinary Cancer Congress
6. Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
7. Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
8. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
9. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
10. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
11. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2017)... and Canada joint tech company Laughing Face has ... detergent, and features a powerful disinfection process. The company ... washes and sanitizes women,s panties or babies, cloth diapers in 25 ... ... an external water inlet. ...
(Date:5/10/2017)... May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of the ... based on extensive data analysis from GHI,s hospitals database ... database for the region. The GHI database covers 86% of ... more than 130 data points for each institution in key ...
(Date:5/10/2017)... 2017 CSSi, the global leader in patient ... industry, is proud to announce the launch of its ... features both enriched content and a customized layout that ... company,s already well-established position as the top global patient ... many months of hard work, we are delighted to ...
Breaking Medicine Technology:
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... the first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for ... applications. “We are thrilled to partner with Cupron® to provide customers with ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... week that is focusing on the Peace Agreements being discussed by President Donald Trump ... in a race to try to speed up peace talks in the continuous battle ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled ... a new, informational blog post on insurance options. If a Bay Area patient has ... help save time and money. Visiting an in-network provider for a second opinion can ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... year’s recipient of proceeds from its 14th Annual Clays for Kids fundraiser, to ... Road 30, Bennett, Colorado. , As part of BluSky’s partnership with The ...
(Date:5/26/2017)... ... 26, 2017 , ... Water damage to the flooring of several classrooms at ... education officials with a number of critical issues to address before students could return ... accomplished with little or no disruption to class schedules. Second, the project had to ...
Breaking Medicine News(10 mins):